Last updated: February 9, 2026
Case Overview
UCB, Inc. filed suit against Alza Corporation under docket number 1:15-cv-01192. The action centers on patent infringement claims related to drug delivery technology. The complaint alleges that Alza's products infringe on UCB's patents covering specific formulations and delivery mechanisms used in pharmaceutical treatments.
Key Timelines
- Filing Date: September 21, 2015
- Initial Complaint: Sought injunctive relief and damages
- Markman Hearing: Conducted November 2016
- Summary Judgment Motions: Filed and ruled upon in 2017
- Trial: Held in August 2018
- Final Judgment: August 2018, with the court ruling in favor of UCB on patent infringement
Patent and Technology Details
- Patent-in-suit: U.S. Patent No. 8,321,650, titled "Controlled-release matrix formulation"
- Patent Claims: Cover specific controlled-release formulations and matrix compositions
- Technology: Involves a biodegradable polymer matrix designed to deliver medication over extended periods
Litigation Claims
UCB claimed Alza's delivery systems directly infringe on the '650 patent through their extended-release formulations. They argued Alza's products incorporate the patented matrix technologies without licensing agreements.
Alza’s defense: Challenged the patent's validity, asserting prior art invalidates key claims and contested infringement allegation.
Court Proceedings
- Claim Construction: The court performed a Markman hearing to interpret key patent terms. Notably, terms like "controlled-release" and "matrix" received specific definitions, influencing infringement and validity arguments.
- Summary Judgment: UCB's motion for infringement was granted; Alza's invalidity arguments were partly denied.
- Trial Findings: The court found that Alza’s products did infringe and that the patent was valid. Damages were awarded based on a reasonable royalty rate.
Judgment and Patent Impact
In August 2018, the court awarded UCB approximately $45 million in damages. The ruling upheld the patent's validity and confirmed infringement, setting a precedent for future controlled-release drug patent enforcement.
Appeals and Post-Judgment Developments
- Alza appealed the decision to the United States Court of Appeals for the Federal Circuit in September 2018.
- As of late 2022, the appellate process remains unresolved with no final appellate decision reported publicly.
Market and Business Implications
The case reinforces the enforceability of controlled-release formulations patents in the pharmaceutical industry, potentially deterring product copying. The damages awarded represent a significant revenue safeguard for UCB’s intellectual property portfolio.
Legal and Industry Analysis
- Patent Validity: The court’s validation highlights the importance of detailed patent claims and clear claim construction in patent litigation.
- Technology Significance: The case underscores the competitive importance of extended-release formulations in drug development and marketing.
- Litigation Trends: Smaller biotech firms and industry giants increasingly litigate over controlled-release technologies, emphasizing patent strength.
Key Takeaways
- UCB’s patent infringement claim was successful in court, leading to substantial damages.
- The case highlights the importance of precise patent claim language and clear claim interpretation.
- Enforceable patents on drug delivery mechanisms continue to shape competitive dynamics in pharmaceuticals.
- The appeal might impact future patent enforcement strategies and licensing negotiations.
- Ongoing litigation highlights the importance of comprehensive patent protections for innovative drug delivery technologies.
FAQs
1. What was the core patent involved in UCB v. Alza?
The case involved UCB’s Patent No. 8,321,650 for a controlled-release matrix formulation.
2. What was the court’s final ruling in 2018?
The court found Alza's products infringed on UCB's patent, declared the patent valid, and awarded UCB approximately $45 million in damages.
3. What are the patent claims primarily about?
Claims cover specific biodegradable polymer matrices used for long-term drug delivery.
4. Has Alza appealed the ruling?
Yes, Alza appealed to the Federal Circuit in September 2018. As of late 2022, the appeal remains unresolved.
5. How does this case influence the pharmaceutical industry?
It affirms the enforceability of extended-release technology patents and discourages infringement through technological copycats.
References
[1] UCB, Inc. v. Alza Corporation, 1:15-cv-01192 (D.D.C. 2015).
